Cornerstone Therapeutics Inc.
1255 Crescent Green Drive
Suite 250
Cary,
NC 27518
United States - Map
Phone: 919-678-6611
Fax: 866-443-3092
Web Site: http://www.crtx.com
| Cornerstone Therapeutics Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for the respiratory market in the United States. Its marketed products include SPECTRACEF for the treatment of mild to moderate infections, such as community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis, pharyngitis and tonsillitis, and uncomplicated skin and skin-structure infections; ZYFLO CR for the prevention and chronic treatment of asthma in adults and children 12 years of age or older; and ALLERX Dose Pack products, which are oral tablets for the temporary relief of symptoms associated with allergic rhinitis. The company also markets HYOMAX line of products, which consist of generic formulations of four antispasmodic medications containing the API hyoscyamine sulfate, an anticholinergic for functional intestinal disorders to reduce symptoms, such as those seen in mild dysenteries and diverticulitis; and BALACET 325, APAP 325, and APAP 500 for the relief of mild to moderate pain. In addition, its products under development include SPECTRACEF Once Daily for acute bacterial exacerbations of chronic bronchitis with COPD; SPECTRACEF Suspension for pharyngitis and tonsillitis, and acute otitis media; CRTX 058 for temporary relief of symptoms associated with allergic rhinitis; and CRTX 067 and CRTX 069 for temporary relief of symptoms associated with cough, and upper respiratory symptoms associated with allergies or a cold. The company is headquartered in Cary, North Carolina. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Craig A. Collard ,
Chairman, Chief Exec. Officer, Pres, Chief Exec. Officer of Cornerstone Biopharma Holdings Ltd and Pres of Cornerstone Biopharma Holdings Ltd |
$
758.00K | N/A | Mr. David Price , 47
Chief Financial Officer, Principal Accounting Officer, Exec. VP of Fin. and Treasurer |
N/A
| N/A | Mr. Steven M. Lutz , 43
Exec. VP of Manufacturing and Trade |
N/A
| N/A | Mr. Andrew K. W. Powell Esq., 52
Exec. VP, Sec. and Gen. Counsel |
N/A
| N/A | Mr. Joshua B. Franklin , 40
VP of Sales and Marketing |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.31% Nasdaq 0.00%
Profile
